Evidence map›Paper›PMID 38617840›Full record

ReviewFrontiers in immunology2024

Complete remission in a pretreated, microsatellite-stable,

Lijuan He, Haiyuan Li, Yunpeng Wang, Weidong Li, Lei Gao, Bo Xu, Jike Hu, Puyi He, Weigao Pu, Guodong Sun and 4 more

Open access · goldAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Lijuan HeLanzhou University Second Hospital, Lanzhou, China.
Haiyuan LiLanzhou University Second Hospital, Lanzhou, China.
Yunpeng WangLanzhou University Second Hospital, Lanzhou, China.
Weidong LiLanzhou University Second Hospital, Lanzhou, China.
Lei GaoLanzhou University Second Hospital, Lanzhou, China.
Bo XuLanzhou University Second Hospital, Lanzhou, China.
Jike HuLanzhou University Second Hospital, Lanzhou, China.
Puyi HeLanzhou University Second Hospital, Lanzhou, China.
Weigao PuLanzhou University Second Hospital, Lanzhou, China.
Guodong SunLanzhou University Second Hospital, Lanzhou, China.
Zhuanfang WangLanzhou University Second Hospital, Lanzhou, China.
Qinying HanLanzhou University Second Hospital, Lanzhou, China.
Ben LiuLanzhou University Second Hospital, Lanzhou, China.
Hao ChenLanzhou University Second Hospital, Lanzhou, China.
Lanzhou University Second Hospital · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic colon cancer remains an incurable disease, and it is difficult for existing treatments to achieve the desired clinical outcome, especially for colon cancer patients who have received first-line treatment. Although immune checkpoint inhibitors (ICIs) have demonstrated durable clinical efficacy in a variety of solid tumors, their response requires an inflammatory tumor microenvironment. However, microsatellite-stable (

Indexed as

Antibodies, Monoclonal, HumanizedColonic NeoplasmsProto-Oncogene Proteins p21(ras)BevacizumabHumansMaleMicrosatellite RepeatsPathologic Complete ResponsePlatinumTumor MicroenvironmentAntibodies, Monoclonal, HumanizedBevacizumabKRAS protein, humanPlatinumProto-Oncogene Proteins p21(ras)sintilimabbevacizumabcolon cancerimmunotherapyKRAS mutationmetastasisMSSrecurrencesintilimab

Identifiers

PMID38617840
PMCPMC11010642
OpenAlexW4393276381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.